Walter M Stadler

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 21

Top Topics

Renal Cell Carcinoma

Top Venues

Clinical cancer research : an official journal of the American Association for Cancer Research

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

JCO precision oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Kunal B Desai, Anthony V Serritella, Walter M Stadler, Peter H O'Donnell, Randy F Sweis, Russell Zelig Szmulewitz
A Phase I Trial of Enzalutamide Plus Selective Glucocorticoid Receptor Modulator Relacorilant in Patients with Metastatic Castration-Resistant Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (11) (2024)
Kunal B Desai, Anthony V Serritella, Walter M Stadler, Peter H O'Donnell, Randy F Sweis, Russell Zelig Szmulewitz
A Phase I Trial of Enzalutamide Plus Selective Glucocorticoid Receptor Modulator Relacorilant in Patients with Metastatic Castration-Resistant Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (11) (2024)
Walter M Stadler, Theodore G Karrison
There Is More to Length of Survival Than Survival: Endpoints in Oncology Trials. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (15) (2024)
Kunal B Desai, Anthony V Serritella, Walter M Stadler, Peter H O'Donnell, Randy F Sweis, Russell Zelig Szmulewitz
A Phase I Trial of Enzalutamide Plus Selective Glucocorticoid Receptor Modulator Relacorilant in Patients with Metastatic Castration-Resistant Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (11) (2024)
Walter M Stadler, Theodore G Karrison
There is More to Length of Survival than Survival: Endpoints in Oncology Trials. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Suzanne George, Nancy Campbell, Shauna L Hillman, Elizabeth S Harlos, David W J Stein, Miranda Y Chan, Selina L Chow, Cassandra L Elrahi, Andre C Quina, Maeve C Kokolus, Michelle D Casagni, Matthias Weiss, Daniel M Anderson, Walter M Stadler, Olivia C Hoff, Donna R Rivera, Paul G Kluetz, Sumithra J Mandrekar, Steven Piantadosi
Feasibility of structuring electronic health record data to facilitate real-world data research: ICAREdata methods applied to multicenter cancer clinical trials. Cancer (2024)
Kunal B Desai, Anthony V Serritella, Walter M Stadler, Peter H O'Donnell, Randy F Sweis, Russell Zelig Szmulewitz
A phase I trial of enzalutamide plus selective glucocorticoid receptor modulator relacorilant in patients with metastatic castration resistant prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Kunal B Desai, Anthony V Serritella, Walter M Stadler, Peter H O'Donnell, Randy F Sweis, Russell Zelig Szmulewitz
A Phase I Trial of Enzalutamide Plus Selective Glucocorticoid Receptor Modulator Relacorilant in Patients with Metastatic Castration-Resistant Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (11) (2024)
Kunal B Desai, Anthony V Serritella, Walter M Stadler, Peter H O'Donnell, Randy F Sweis, Russell Zelig Szmulewitz
A Phase I Trial of Enzalutamide Plus Selective Glucocorticoid Receptor Modulator Relacorilant in Patients with Metastatic Castration-Resistant Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (11) (2024)
Bradley Alexander McGregor, Wanling Xie, Elio Adib, Walter M Stadler, Yousef Zakharia, Aijai Alva, M Dror Michaelson, Shilpa Gupta, Elaine T Lam, Subrina Farah, Amin H Nassar, Xiao X Wei, Kerry L Kilbridge, Lauren C Harshman, Sabina Signoretti, Lynette M Sholl, David J Kwiatkowski, Rana R McKay, Toni K Choueiri
Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma. JCO precision oncology 6 (2022)
Michael R Harrison, Brian A Costello, Nrupen A Bhavsar, Ulka Vaishampayan, Sumanta Kumar Pal, Yousef Zakharia, Heather S L Jim, Mayer N Fishman, Ana M Molina, Christos E Kyriakopoulos, Che-Kai Tsao, Leonard J Appleman, Benjamin A Gartrell, Arif Hussain, Walter M Stadler, Neeraj Agarwal, Russell K Pachynski, Thomas E Hutson, Hans J Hammers, Christopher W Ryan, Brant A Inman, Jack Mardekian, Azah Borham, Daniel J George
Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC). Cancer 127 (13) (2021)
Walter M Stadler, Fay J Hlubocky, Feighanne Hathaway
Knowledge and distress in complex cancer care. Cancer (2021)
Richard T Lee, Nancy Kwon, Jimin Wu, Connie To, Steven To, Russell Szmulewitz, Raffi Tchekmedyian, Holly M Holmes, Olufunmilayo I Olopade, Walter M Stadler, Jamie Von Roenn
Prevalence of potential interactions of medications, including herbs and supplements, before, during, and after chemotherapy in patients with breast and prostate cancer. Cancer 127 (11) (2021)
Jonathan E Rosenberg, Karla A Ballman, Susan Halabi, Pamela J Atherton, Amir Mortazavi, Christopher J Sweeney, Walter M Stadler, Benjamin A Teply, Joel Picus, Scott T Tagawa, Sreedhar Katragadda, Daniel Vaena, Jamal Misleh, Christopher J Hoimes, Elizabeth R Plimack, Thomas W Flaig, Robert Dreicer, Dean F Bajorin, Olwen Hahn, Eric J Small, Michael J Morris
Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (22) (2021)
Sara E Kochanny, Francis P Worden, Douglas R Adkins, Dean W Lim, Julie E Bauman, Stephanie A Wagner, Ryan J Brisson, Theodore G Karrison, Walter M Stadler, Everett E Vokes, Tanguy Y Seiwert
A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma. Cancer 126 (10) (2020)
Rana R McKay, Bradley Alexander McGregor, Wanling Xie, David A Braun, Xiao Wei, Christos E Kyriakopoulos, Yousef Zakharia, Benjamin L Maughan, Tracy L Rose, Walter M Stadler, David F McDermott, Lauren C Harshman, Toni K Choueiri
Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 38 (36) (2020)
Tanguy Y Seiwert, Sara E Kochanny, Kevin Wood, Francis P Worden, Douglas R Adkins, James L Wade, Bethany G Sleckman, Daniel Anderson, Ryan J Brisson, Theodore Karrison, Walter M Stadler, Everett E Vokes
A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab-resistant head and neck cancer: The MAESTRO study. Cancer 126 (14) (2020)
Walter M Stadler
No interest, no conflict. Cancer 126 (16) (2020)
Matthew R Danzig, Katherine Mallin, James M McKiernan, Walter M Stadler, Srikala S Sridhar, Todd M Morgan, Bernard H Bochner, Cheryl T Lee
Prognostic importance of lymphovascular invasion in urothelial carcinoma of the renal pelvis. Cancer 124 (12) (2018)
Rebecca Wellmann, Brittany A Borden, Keith Danahey, Rita Nanda, Blasé N Polite, Walter M Stadler, Mark J Ratain, Peter H O'Donnell
Analyzing the clinical actionability of germline pharmacogenomic findings in oncology. Cancer 124 (14) (2018)
Tanya Barauskas Dorff, Jeff A Longmate, Sumanta K Pal, Walter M Stadler, Mayer N Fishman, Ulka N Vaishampayan, Amol Rao, Jacek K Pinksi, James S Hu, David I Quinn, Primo N Lara
Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer. Cancer 123 (23) (2017)